Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Rivian Automotive Plans To Construct Wind Turbine At Illinois Campus

Rivian Automotive Inc (NASDAQ:RIVN) plans to establish a large-scale wind turbine at its Normal manufacturing campus in Illinois. The automaker expects to generate clean energy to enable new R1 vehicles to be powered by renewables for their first charge. Rivian installed a 783-kilowatt solar canopy in early 2022, which is scheduled to begin…

Lucid Group Opens Retail Studio In Colorado

Lucid Group Opens Retail Studio In Colorado

Electric car maker Lucid Group Inc (NASDAQ:LCID) has opened its first studio location in Denver, Colorado, at the Cherry Creek Shopping Center. The studio marks twenty-seven studios and service center locations open in North America. The Lucid Studio in Cherry Creek will be open to the public on June 18. "The state of…

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors. BMO writes that Graphite's platform is expected to be safer than existing…

Legend Biotech Shares Move Higher After Bullish BMO Pitch

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due…

inkl

Read news from The Economist, FT, and more,
with one subscription

10 Information Technology Stocks With Whale Alerts In Today's Session

10 Information Technology Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.

Here's How Much $1000 Invested In Verisk Analytics 10 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Verisk Analytics 10 Years Ago Would Be Worth Today

Verisk Analytics (NASDAQ:VRSK) has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 12.86%. Currently, Verisk Analytics has a market capitalization of $25.64 billion.

As Bears Grip Tesla Stock, Here's Where To Watch For The Bounce

As Bears Grip Tesla Stock, Here's Where To Watch For The Bounce

Tesla Inc (NASDAQ: TSLA) was trading about 2% higher on Friday, rebounding slightly from a bearish day on Thursday, which saw the stock slide about 4% in tandem with the general markets.

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

More Game Of Thrones Content Is Coming With A Jon Snow Series: What Investors Should Know

More Game Of Thrones Content Is Coming With A Jon Snow Series: What Investors Should Know

The "Game of Thrones" franchise will live on with a highly anticipated sequel series — just the latest in a string of spinoff programming inspired by the popular HBO show that spanned eight seasons.

Needham Remained Bullish On KLA Corp Post Investor Day - Read Why

Needham Remained Bullish On KLA Corp Post Investor Day - Read Why

Needham hailed KLA Corp's (NASDAQ: KLAC) 2022 Investor Day in NYC in a note titled "Investor Day Reveals New 2026 Model Targeting Revenue of $14bn and EPS of $38."

Get all your
news in one place.

100's of premium titles.
One news app.

Raymond James Lists Its Top Stock Picks In Online Ad

Raymond James hosted an online advertising conference call with an industry expert. The expert has visibility into ~$2 billion of spend with a mix similar to the ad industry and diversified across Fortune 1,000 advertisers.

Needham Considers It Futile For Meta To Compete With TikTok, YouTube, Amazon, Google

Needham's Laura Martin said Meta Platforms Inc's (NASDAQ: META) falling brand value is a lead indicator for rising customer acquisition costs, churn levels, and declining pricing power.

Dow Jones Turns Lower; Revlon Shares Jump

U.S. stocks pared gains midway through trading, with the Dow Jones dropping around 100 points on Friday.

33 Stocks Moving In Friday's Mid-Day Session

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.

Get all your
news in one place.

100's of premium titles.
One news app.

What 11 Analyst Ratings Have To Say About Hub Group

Within the last quarter, Hub Group (NASDAQ:HUBG) has observed the following analyst ratings:

Expert Ratings for KLA

Analysts have provided the following ratings for KLA (NASDAQ:KLAC) within the last quarter:

Where Peloton Interactive Stands With Analysts

Peloton Interactive (NASDAQ:PTON) has observed the following analyst ratings within the last quarter:

Here's How Much $1000 Invested In Texas Instruments 20 Years Ago Would Be Worth Today

Texas Instruments (NASDAQ:TXN) has outperformed the market over the past 20 years by 2.92% on an annualized basis producing an average annual return of 9.75%. Currently, Texas Instruments has a market capitalization of $138.82 billion.

Expert Ratings for Fifth Third Bancorp

Analysts have provided the following ratings for Fifth Third Bancorp (NASDAQ:FITB) within the last quarter:

Keybanc Maintains Overweight Rating for KLA: Here's What You Need To Know

Keybanc has decided to maintain its Overweight rating of KLA (NASDAQ:KLAC) and lower its price target from $440.00 to $375.00. Shares of KLA are trading down 0.13% over the last 24 hours, at $310.00 per share. A move to $375.00 would account for a 20.97% increase from the current share…

Piper Sandler Maintains Overweight Rating for Equity Bancshares: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Equity Bancshares (NASDAQ:EQBK) and lower its price target from $38.00 to $35.00. Shares of Equity Bancshares are trading up 1.65% over the last 24 hours, at $30.79 per share.

1 … 382 383 384 385

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Warner Bros Discovery

Texas Instruments

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Renewable Energy

Places

363,132 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play